

Changing trends in the risk factors for second primary malignancies after autologous stem cell transplantation for multiple myeloma before and after the introduction of proteasome inhibitors and immunomodulatory drugs

Hiroyuki Takamatsu,¹ Tomohiro Matsuda,² Shohei Mizuno,³ Tsutomu Takahashi,⁴ Shin-ichi Fuchida,⁵ Ichiro Hanamura,³ Keisuke Kataoka,^{6,7} Nobuhiro Tsukada,⁸ Morio Matsumoto,⁹ Akira Hangaishi,¹⁰ Noriko Doki,¹¹ Naoyuki Uchida,¹² Masashi Sawa,¹³ Yumiko Maruyama,¹⁴ Shingo Kurahashi,¹⁵ Koji Nagafuji,¹⁶ Yoriko Harazaki,¹⁷ Shinichi Kako,¹⁸ Shinsuke Iida,¹⁹ Tatsuo Ichinohe,²⁰ Yoshinobu Kanda,^{18,21} Yoshiko Atsuta^{22,23} and Kazutaka Sunami²⁴

¹Department of Hematology, Kanazawa University, Kanazawa; ²Division of International Health Policy Research, National Cancer Center Institute for Cancer Control, Tokyo; ³Division of Hematology, Department of Internal Medicine, Aichi Medical University, Nagakute; ⁴Department of Hematology, Shimane University Hospital, Izumo; ⁵Department of Hematology, Japan Community Health care Organization Kyoto Kuramaguchi Medical Center, Kyoto; ⁶Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo; ⁷Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo; ⁸Division of Hematology, Japanese Red Cross Medical Center, Tokyo; ⁹Department of Hematology, National Hospital Organization Shibukawa Medical Center, Shibukawa; ¹⁰Department of Hematology, National Center for Global Health and Medicine, Tokyo; ¹¹Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo; ¹²Department of Hematology, Federation of National Public Service Personnel Mutual Aid Associations, Toranomom Hospital, Tokyo; ¹³Department of Hematology and Oncology, Anjo Kosei Hospital, Anjo; ¹⁴Department of Hematology, University of Tsukuba Hospital, Tsukuba; ¹⁵Division of Hematology and Oncology, Toyohashi Municipal Hospital, Toyohashi; ¹⁶Division of Hematology and Oncology, Department of Medicine, Kurume University Hospital, Kurume; ¹⁷Division of Hematology, Miyagi Cancer Center, Natori; ¹⁸Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama; ¹⁹Division of Hematology and Oncology, Nagoya City University Hospital, Nagoya; ²⁰Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima; ²¹Division of Hematology, Department of Medicine, Jichi Medical University, Shimotsuke; ²²Japanese Data Center for Hematopoietic Cell Transplantation, Nagakute; ²³Department of Registry Science for Transplant and Cellular Therapy, Aichi Medical University School of Medicine, Nagakute and ²⁴Department of Hematology, National Hospital Organization Okayama Medical Center, Okayama, Japan

Correspondence: H. Takamatsu
takamaz@staff.kanazawa-u.ac.jp

Received: March 27, 2023.

Accepted: July 10, 2023.

Early view: July 20, 2023.

<https://doi.org/10.3324/haematol.2023.283202>

©2023 Ferrata Storti Foundation

Published under a CC BY-NC license



Figure S1




Figure S1. Number of patients according to the follow-up time since transplantation

Figure S2




Figure S2. Overall survival (OS) according to (A) age at transplant; (B) sex; (C) use of proteasome inhibitors (PIs) and/or immunomodulatory drugs (IMiDs); (D) tandem or single transplant.